The 36-month beta value for ATHE is at 0.93. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATHE is 8.32M, and currently, shorts hold a 0.28% of that float. The average trading volume for ATHE on April 25, 2024 was 83.19K shares.
ATHE) stock’s latest price update
Alterity Therapeutics Ltd ADR (NASDAQ: ATHE)’s stock price has increased by 9.39 compared to its previous closing price of 2.13. However, the company has seen a 15.92% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-10 that MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA.
ATHE’s Market Performance
ATHE’s stock has risen by 15.92% in the past week, with a monthly rise of 36.26% and a quarterly rise of 21.35%. The volatility ratio for the week is 10.40% while the volatility levels for the last 30 days are 12.98% for Alterity Therapeutics Ltd ADR The simple moving average for the last 20 days is 11.68% for ATHE stock, with a simple moving average of -2.05% for the last 200 days.
ATHE Trading at 20.55% from the 50-Day Moving Average
After a stumble in the market that brought ATHE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.93% of loss for the given period.
Volatility was left at 12.98%, however, over the last 30 days, the volatility rate increased by 10.40%, as shares surge +29.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.50% upper at present.
During the last 5 trading sessions, ATHE rose by +15.92%, which changed the moving average for the period of 200-days by -15.73% in comparison to the 20-day moving average, which settled at $2.11. In addition, Alterity Therapeutics Ltd ADR saw -6.43% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ATHE
Current profitability levels for the company are sitting at:
- -3.52 for the present operating margin
- 0.93 for the gross margin
The net margin for Alterity Therapeutics Ltd ADR stands at -3.37. The total capital return value is set at -0.12. Equity return is now at value -52.42, with -43.13 for asset returns.
Based on Alterity Therapeutics Ltd ADR (ATHE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -68.52.
Currently, EBITDA for the company is -15.19 million with net debt to EBITDA at 5.46. When we switch over and look at the enterprise to sales, we see a ratio of 19.36. The receivables turnover for the company is 0.09for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
In conclusion, Alterity Therapeutics Ltd ADR (ATHE) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
